Literature DB >> 26711129

(18)F-Fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer.

Junichi Nishimura1,2, Junichi Hasegawa3, Yoji Ogawa4, Hideaki Miwa5, Mamoru Uemura1, Naotsugu Haraguchi1, Taishi Hata1, Hirofumi Yamamoto1, Ichiro Takemasa1, Tsunekazu Mizushima1, Riichiro Nezu2, Yuichiro Doki1, Masaki Mori1.   

Abstract

PURPOSE: Early detection of a response to neoadjuvant chemotherapy for locally advanced rectal cancer may spare patients from additional toxic but ineffective chemotherapy. Using (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET), we evaluated tumor response prospectively in the early course of preoperative chemotherapy.
METHODS: The subjects were 15 patients who received neoadjuvant chemotherapy (XELOX or XELOX plus bevacizumab) for locally advanced rectal cancer. Patients underwent (18)F-FDG PET before chemotherapy, at the end of the first cycle of chemotherapy, and before surgical resection. Magnetic resonance imaging (MRI) was performed before chemotherapy, after the second cycle of chemotherapy, and before resection. After resection, the SUVmax and diameter were compared and graded according to the tumor regression grade (TRG).
RESULTS: The TRG was assessed as TRG1 in one patient, TRG2 in five patients, and TRG3 in nine patients. We divided the patients into two groups: non-responders (NR) included the TRG1 and TRG2 patients, and responders (R) included the TRG3 patients. The tumor size before surgery was significantly smaller in the R group than in the NR group. The SUVmax at the end of the first cycle of chemotherapy and before surgical resection was significantly lower in the R group than in the NR group.
CONCLUSION: Performing (18)F-FDG PET at the end of the first cycle of chemotherapy allowed us to predict the pathological response of locally advanced rectal cancer.

Entities:  

Keywords:  FDG-PET; Neoadjuvant chemotherapy; Rectal cancer

Mesh:

Substances:

Year:  2015        PMID: 26711129     DOI: 10.1007/s00595-015-1297-x

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  37 in total

1.  Long-term effect of preoperative radiation therapy on anorectal function.

Authors:  Johan Pollack; Torbjörn Holm; Björn Cedermark; Bo Holmström; Anders Mellgren
Journal:  Dis Colon Rectum       Date:  2006-03       Impact factor: 4.585

2.  Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.

Authors:  Deborah Schrag; Martin R Weiser; Karyn A Goodman; Mithat Gonen; Ellen Hollywood; Andrea Cercek; Diane L Reidy-Lagunes; Marc J Gollub; Jinru Shia; Jose G Guillem; Larissa K F Temple; Philip B Paty; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

3.  Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial.

Authors:  Corrie A M Marijnen; Cornelis J H van de Velde; Hein Putter; Mandy van den Brink; Cornelis P Maas; Hendrik Martijn; Harm J Rutten; Theo Wiggers; Elma Klein Kranenbarg; Jan-Willem H Leer; Anne M Stiggelbout
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

4.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

5.  Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy?

Authors:  Yoichiro Yoshida; Seiichiro Hoshino; Naoya Aisu; Ai Mogi; Teppei Yamada; Daibo Kojima; Syu Tanimura; Keiji Hirata; Yuichi Yamashita
Journal:  Support Care Cancer       Date:  2014-11-23       Impact factor: 3.603

6.  Preoperative radiochemotherapy is successful also in patients with locally advanced rectal cancer who have intrinsically high apoptotic tumours.

Authors:  M J E M Gosens; R C Dresen; H J T Rutten; G A P Nieuwenhuijzen; J A W M van der Laak; H Martijn; I Tan-Go; I D Nagtegaal; A J C van den Brule; J H J M van Krieken
Journal:  Ann Oncol       Date:  2008-07-29       Impact factor: 32.976

7.  Mesorectal excision for rectal cancer.

Authors:  J K MacFarlane; R D Ryall; R J Heald
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

8.  Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.

Authors:  Keisuke Uehara; Kazuhiro Hiramatsu; Atsuyuki Maeda; Eiji Sakamoto; Masaya Inoue; Satoshi Kobayashi; Yuichiro Tojima; Yuichiro Yoshioka; Goro Nakayama; Hiroshi Yatsuya; Naoki Ohmiya; Hidemi Goto; Masato Nagino
Journal:  Jpn J Clin Oncol       Date:  2013-08-09       Impact factor: 3.019

9.  Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy.

Authors:  Brunella Barbaro; Cecilia Fiorucci; Carmen Tebala; Vincenzo Valentini; Maria Antonietta Gambacorta; Fabio Maria Vecchio; Gianluca Rizzo; Claudio Coco; Antonio Crucitti; Carlo Ratto; Lorenzo Bonomo
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

10.  Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer.

Authors:  Jose G Guillem; Harvey G Moore; Timothy Akhurst; David S Klimstra; Leyo Ruo; Madhu Mazumdar; Bruce D Minsky; Leonard Saltz; W Douglas Wong; Steven Larson
Journal:  J Am Coll Surg       Date:  2004-07       Impact factor: 6.113

View more
  1 in total

Review 1.  A decade of multi-modality PET and MR imaging in abdominal oncology.

Authors:  Lisa A Min; Francesca Castagnoli; Wouter V Vogel; Jisk P Vellenga; Joost J M van Griethuysen; Max J Lahaye; Monique Maas; Regina G H Beets Tan; Doenja M J Lambregts
Journal:  Br J Radiol       Date:  2021-08-13       Impact factor: 3.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.